LRMR Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

3.450

Open

3.350

VWAP

3.36

Vol

1.74M

Mkt Cap

354.24M

Low

3.210

Amount

5.85M

EV/EBITDA(TTM)

Total Shares

103.88M

141.39M

EV/OCF(TTM)

P/S(TTM)

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

Events Timeline

(ET)

2026-06-29

16:30:00

Major Averages Finish Broadly Higher as Investors Await Middle East News

2026-06-29

12:00:00

Major Averages Broadly Higher as Investors Await Middle East News

2026-06-29

10:30:00

Larimar Therapeutics Shares Drop 17% After New Safety Findings

2026-06-29

07:00:00

Larimar Therapeutics Submits FDA Accelerated Approval Application

News

7.0

07-07Globenewswire

Investigation Launched into Larimar Therapeutics for Possible Securities Fraud

8.5

07-02stocktwits

Larimar Therapeutics Regulatory Progress Highlights Value Potential

7.0

07-02PRnewswire

Pomerantz LLP Investigates Securities Fraud Claims Against Larimar Therapeutics

9.0

06-29NASDAQ.COM

Larimar Submits Biologics License Application for Nomlabofusp

8.5

06-29stocktwits

Larimar Submits Biologics License Application for Friedreich's Ataxia Treatment

8.5

06-29Newsfilter

Larimar Submits Biologics License Application for Nomlabofusp

4 Analyst Rating

Wall Street analysts forecast LRMR stock price to rise

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

21.00

Averages

21.50

High

22.00

Current: 0.000

Low

21.00

Averages

21.50

High

22.00

H.C. Wainwright

Buy

initiated

$10

AI Analysis

2026-07-02

Reason

H.C. Wainwright

Price Target

$10

AI Analysis

2026-07-02

initiated

Buy

Reason

H.C. Wainwright assumed coverage of Larimar Therapeutics with a Buy rating and $10 price target. The company's biologics license application for nomlabofusp later this year is likely to receive priority review, the analyst tells investors in a research note. The firm forecasts a commercial launch of nomlabofusp in 2027 with sales of $47.9M that year, growing to peak annual sales of over $1.1B by 2040.

Baird

Christopher Chen

Outperform

downgrade

$7 -> $5

2026-06-30

Reason

Baird

Christopher Chen

Price Target

$7 -> $5

2026-06-30

downgrade

Outperform

Reason

Baird analyst Christopher Chen lowered the firm's price target on Larimar Therapeutics to $5 from $7 and keeps an Outperform rating on the shares. The firm updated its model followingits Nomlabofuso update which showed signs of clinical benefits but dogged safety risk.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LRMR

Unlock Now

Valuation Metrics

The current forward P/E ratio for Larimar Therapeutics Inc (LRMR.O) is 0.00, compared to its 5-year average forward P/E of -3.43. For a more detailed relative valuation and DCF analysis to assess Larimar Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.43

Current PE

0.00

Overvalued PE

-1.66

Undervalued PE

-5.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.39

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.15

Undervalued EV/EBITDA

-2.93

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.65

Current PS

5.93

Overvalued PS

2.62

Undervalued PS

-1.33

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

news about stocks that are below 10 dollar

Intellectia · 100 candidates

Region: USPrice: $1.00 - $10.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000News Driver: Positive, Negative

Ticker

Name

Market Cap$

XWEL

XWELL Inc

6.98M

LRMR

Larimar Therapeutics Inc

494.39M

VSME

VS Media Holdings Ltd

5.06M

EVH

Evolent Health Inc

350.52M

NVTS

Navitas Semiconductor Corp

2.27B

SBET

Sharplink Inc

1.46B

predict biggest winner ticker this year

Intellectia · 73 candidates

Market Cap: 100.00M - 30.00BBeta: HighRiskList Exchange: XNYS, XNAS, XASEOne Month Rise Prob: >= 55One Month Predict Return: >= 10.0%

Ticker

Name

Market Cap$

JMIA

Jumia Technologies AG

1.14B

LII

Lennox International Inc

19.72B

DAVE

Dave Inc

2.39B

LODE

Comstock Inc

196.99M

SMCI

Super Micro Computer Inc

18.29B

FTCI

FTC Solar Inc

141.78M

Whales Holding LRMR

Deerfield Management Company, L.P.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Larimar Therapeutics Inc (LRMR) stock price today?

The current price of LRMR is 3.41 USD — it has increased 3.65

What is Larimar Therapeutics Inc (LRMR)'s business?

What is the price predicton of LRMR Stock?

Wall Street analysts forecast LRMR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LRMR is21.50 USD with a low forecast of 21.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.